Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Information Consistency of Clinically Significant Drug Interactions in Tyrosine Kinase Inhibitors

타이로신키나아제 억제제의 임상적으로 유의한 약물상호작용 정보 일관성 분석

  • An, Seulki (College of Pharmacy, Gachon University) ;
  • Lee, Ju-Yeun (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University) ;
  • Ah, Young-Mi (College of Pharmacy, Yeungnam University)
  • 안슬기 (가천대학교 약학대학) ;
  • 이주연 (서울대학교 약학대학, 서울대학교 종합약학연구소) ;
  • 아영미 (영남대학교 약학대학)
  • Received : 2020.02.26
  • Accepted : 2020.03.10
  • Published : 2020.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Drug-drug interactions (DDIs) in patients using oral anticancer treatment are more common than in those using injectable anticancer agents. In addition, DDIs related to anticancer treatment are known to cause clinically significant outcomes, such as treatment failure and severe toxicity. To prevent these negative outcomes, significant DDIs are monitored and managed using the information provided in drug databases. We aimed to evaluate the consistency of information on clinically significant DDIs for tyrosine kinase inhibitors (TKIs) between representative drug databases. Methods: We selected clinically significant DDIs involving medications that are co-prescribed with TKIs and met the following criteria: the severity level of DDIs was equal or greater than "D" in Lexicomp® or "major" in Micromedex®. We then analyzed the consistency of the severity classification and evidence level between the drug databases. Spearman's correlation coefficient was used to identify the relationship between DDI information in the drug databases. Results: In total, 627 DDI pairs were identified as clinically significant; information on these was provided by Lexicomp® and Micromedex® for 571 and 438 pairs, respectively, and both drug databases provided information on 382 DDI pairs. There was no correlation between the severity and evidence level of DDIs provided in the two databases; Spearman's correlation coefficient for Lexicomp® and Micromedex® was -0.009 (p=0.861) and -0.064 (p=0.209), respectively. Conclusion: To judge the significance of DDIs, healthcare providers should consider that the information on DDIs may be different between drug information databases; hence, clinical factors must be considered concurrently.

Keywords

References

  1. van Leeuwen RW, Brundel DH, Neef C, et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer. 2013;108(5):1071-8. https://doi.org/10.1038/bjc.2013.48
  2. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ. Twelvemonth frequency of drug-metabolizing enzyme and transporterbased drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc. 2013;88(2):139-48. https://doi.org/10.1016/j.mayocp.2012.10.020
  3. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55(2):117-42. https://doi.org/10.1016/j.critrevonc.2005.03.007
  4. Hersh LR, Beldowski K, Hajjar ER. Polypharmacy in the Geriatric Oncology Population. Curr Oncol Rep. 2017;19(11):73. https://doi.org/10.1007/s11912-017-0632-3
  5. Wong CM, Ko Y, Chan A. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. Ann Pharmacother. 2008;42(12):1737-48. https://doi.org/10.1345/aph.1L255
  6. Kim SH, Suh Y, Ah YM, Jun K, Lee JY. Real-world prevalence of potential drug-drug interactions involving oral antineoplastic agents: a population-based study. Support Care Cancer. 2019. doi: 10.1007/s00520-019-05204-2. [Epub ahead of print]
  7. Gay C, Toulet D, Le Corre P. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. Hematol Oncol. 2017;35(3):259-80. https://doi.org/10.1002/hon.2335
  8. Keller KL, Franquiz MJ, Duffy AP, Trovato JA. Drug-drug interactions in patients receiving tyrosine kinase inhibitors. J Oncol Pharm Pract. 2018;24(2):110-5. https://doi.org/10.1177/1078155216682311
  9. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315-26. https://doi.org/10.1016/S1470-2045(13)70579-5
  10. Jeong S, Kam G, Li J, et al. Assessment of consistency of drug interaction information in drug labels among the US, the UK, China, Japan, and Korea. Clin Pharmacol Ther. 2019;105(2):505-14. https://doi.org/10.1002/cpt.1167
  11. Vitry AI. Comparative assessment of four drug interaction compendia. Br J Clin Pharmacol. 2007;63(6):709-14. https://doi.org/10.1111/j.1365-2125.2006.02809.x
  12. U.S. Food & Drug Administration. Drug development and drug interactions: Table of substrates, inhibitors and inducers. Available from https://www.fda.gov/drugs/drug-interactions-labeling/drugdevelopment-and-drug-interactions-table-substrates-inhibitors-andinducers Accessed February 10, 2020.
  13. MHLW. Drug interaction guideline for drug development and labeling recommendations (draft for public comment) Available from "file:///C:/Users/IT/Downloads/Japanese_DDI_guideline_(draft)_2014Jan.pdf Accessed February 10, 2020.
  14. Alfred P. JDB, Michael K. Ponton. Social Science Research Design and Statistics: A Practitioner's Guide to Research Methods and IBM SPSS analysis 2nd edition. Watetree Press LLC
  15. Ekstein D, Tirosh M, Eyal Y, Eyal S. Drug interactions involving antiepileptic drugs: assessment of the consistency among three drug compendia and FDA-approved labels. Epilepsy Behav. 2015;44:218-24. https://doi.org/10.1016/j.yebeh.2015.02.009
  16. Meslin SMM, Zheng WY, Day RO, Tay EMY, Baysari MT. Evaluation of clinical relevance of drug-drug interaction alerts prior to implementation. Appl Clin Inform. 2018;9(4):849-55. https://doi.org/10.1055/s-0038-1676039
  17. Acton EK, Willis AW, Gelfand MA, Kasner SE. Poor concordance among drug compendia for proposed interactions between enzymeinducing antiepileptic drugs and direct oral anticoagulants. Pharmacoepidemiol Drug Saf. 2019;28(11):1534-8. https://doi.org/10.1002/pds.4896
  18. Liu X, Hatton RC, Zhu Y, et al. Consistency of psychotropic drugdrug interactions listed in drug monographs. J Am Pharm Assoc (2003). 2017;57(6):698-703.e692. https://doi.org/10.1016/j.japh.2017.07.008
  19. Yoon D, Song I, Noh Y, Li J, Shin JY. Consistency of listed indications and contraindications between the U.S., the U.K., Japan, and Korea on prescription drug labels. Regul Toxicol Pharmacol. 2018;98:168-70. https://doi.org/10.1016/j.yrtph.2018.07.024